Topical Corticosteroid Adrenal Suppression Risk Precludes OTC Use, Advisory Committe Says
This article was originally published in The Pink Sheet Daily
Topical corticosteroid HPA axis suppression risk under "maximal use conditions" should preclude the OTC marketing of the dermatologic products, FDA advisory committees say. Test for hypothalamus, pituitary, adrenal axis suppression is only 70% accurate, committee members note.
You may also be interested in...
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.
Companies will share data from the proof-of-concept study, but they do not intend to commercially pursue the use of both drugs in combination.